Evidence-Based Patient Guide · Updated April 2026

When Antidepressants Don't Work: How Ketamine Is Changing Treatment-Resistant Depression

If you've tried multiple antidepressants without relief, you're not alone. Roughly one in three people with major depression don't respond to standard medications. Ketamine therapy represents a fundamentally different approach — one that works through new brain pathways and can produce results in hours instead of weeks.

Understand Your Options Compare Providers
30% of MDD patients develop TRD
60-70% response rate to ketamine
Hours to feel initial relief
Understanding Your Diagnosis

What Is Treatment-Resistant Depression?

Treatment-resistant depression (TRD) is a clinical term used when a patient with major depressive disorder (MDD) has not achieved adequate improvement after trying at least two different antidepressant medications, each taken at a proper therapeutic dose for a sufficient duration — typically six to eight weeks per medication. It is not a reflection of personal weakness or a failure on the patient's part; rather, it indicates that the specific biological pathways targeted by conventional antidepressants are not the primary drivers of depression in that individual.

The prevalence of treatment-resistant depression is more common than most people realize. According to data from the National Institute of Mental Health (NIMH) and the landmark STAR*D trial, approximately 30% of the nearly 21 million American adults who experience major depressive episodes each year will meet the criteria for TRD. That translates to roughly 6 to 7 million people in the United States alone whose depression does not respond to first- and second-line antidepressant therapy. Globally, the numbers are even more staggering, with the World Health Organization estimating that depression affects over 280 million people worldwide.

The impact of treatment-resistant depression on quality of life is severe and far-reaching. Patients with TRD experience significantly greater functional impairment than those whose depression responds to medication. This includes difficulty maintaining employment, strained or broken relationships, inability to perform daily activities, chronic fatigue, cognitive impairment often described as "brain fog," and a dramatically increased risk of suicidal ideation and attempts. Studies published in the Journal of Clinical Psychiatry have found that patients with TRD have healthcare costs roughly double those of patients with treatment-responsive depression, and their disability burden is comparable to chronic conditions like congestive heart failure.

For decades, patients with TRD were left with limited options: cycling through additional antidepressants, augmenting with mood stabilizers or antipsychotics, or pursuing electroconvulsive therapy (ECT). While these approaches help some patients, the overall response rates remain disappointing. This therapeutic gap is precisely why the emergence of ketamine as a rapid-acting antidepressant has generated such tremendous excitement in the psychiatric community. It represents the first fundamentally new mechanism of action for treating depression in over 60 years.

Do You Have Treatment-Resistant Depression?

You may have TRD if you've experienced all of the following:

  • Diagnosed with major depressive disorder by a qualified clinician
  • Tried at least two different antidepressant medications
  • Took each medication at an adequate dose for at least 6-8 weeks
  • Did not experience meaningful symptom relief from either medication

Only a licensed mental health professional can formally diagnose TRD. If you suspect your depression is treatment-resistant, discuss your medication history with your psychiatrist or primary care provider.

The Science

How Ketamine Works for Depression

To understand why ketamine is so groundbreaking for treatment-resistant depression, it helps to understand how it differs from every antidepressant that came before it. Traditional antidepressants — SSRIs like fluoxetine (Prozac) and sertraline (Zoloft), SNRIs like venlafaxine (Effexor) and duloxetine (Cymbalta), tricyclics, and MAOIs — all primarily work by modulating monoamine neurotransmitters: serotonin, norepinephrine, and dopamine. These medications increase the availability of these chemical messengers in the synaptic cleft, the gap between neurons where signals are transmitted. While this approach works for many patients, the monoamine hypothesis of depression has proven incomplete, and patients whose depression stems from other neurobiological mechanisms are left without effective options.

The Glutamate System: A Different Target Entirely

Ketamine works through an entirely different neurotransmitter system: the glutamate system. Glutamate is the most abundant excitatory neurotransmitter in the brain, involved in roughly 90% of all excitatory synaptic transmission. Ketamine acts primarily as an NMDA (N-methyl-D-aspartate) receptor antagonist, meaning it blocks a specific type of glutamate receptor. This blockade sets off a remarkable cascade of downstream effects that ultimately lead to rapid antidepressant action.

When ketamine blocks NMDA receptors on inhibitory interneurons in the brain, it paradoxically increases glutamate release in certain brain regions, particularly the prefrontal cortex and hippocampus — areas critically involved in mood regulation, decision-making, and memory. This surge of glutamate then activates another type of receptor called AMPA receptors, which triggers the release of brain-derived neurotrophic factor (BDNF), a protein essential for neuron growth and survival.

Neuroplasticity: Rebuilding Brain Connections

Perhaps the most exciting aspect of ketamine's mechanism is its effect on neuroplasticity — the brain's ability to form new neural connections. Research from Yale University, led by Dr. Ronald Duman and colleagues, has demonstrated that ketamine rapidly increases the number and function of synaptic connections in the prefrontal cortex. Using advanced imaging techniques, these researchers showed that a single dose of ketamine can restore synaptic connections that were damaged by chronic stress — and it does so within hours, not weeks [1].

This synaptic restoration is mediated through the mTOR (mechanistic target of rapamycin) signaling pathway, a molecular cascade that promotes the synthesis of proteins needed to build new synapses. Studies published in Science and Nature have confirmed that ketamine's rapid antidepressant effects are dependent on this mTOR-mediated synaptogenesis. In animal models of depression, ketamine reversed the synaptic deficits caused by chronic stress within 24 hours — a timeline that is simply impossible with traditional antidepressants [2].

Rapid Onset: Hours and Days vs. Weeks and Months

The speed of ketamine's antidepressant action is arguably its most clinically significant advantage. While traditional antidepressants typically require 4 to 8 weeks to produce meaningful improvement — and many patients try multiple medications over months or years — ketamine can produce measurable reductions in depression severity within hours of a single administration. A landmark study from the National Institute of Mental Health (NIMH), published in Biological Psychiatry, found that 71% of patients with treatment-resistant depression responded to a single IV ketamine infusion within 24 hours, with many reporting improvement within just 2 to 4 hours [3].

This rapid onset is not just a matter of convenience — it can be life-saving. For patients experiencing acute suicidal ideation, the weeks-long wait for a traditional antidepressant to take effect represents a dangerous window of vulnerability. Ketamine's ability to rapidly reduce suicidal thoughts has been documented in multiple clinical trials and is one of the driving factors behind the FDA's approval of intranasal esketamine (Spravato) for treatment-resistant depression and depressive episodes with acute suicidal ideation [4].

References

  1. Li, N., et al. (2010). "mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists." Science, 329(5994), 959-964.
  2. Duman, R. S., & Aghajanian, G. K. (2012). "Synaptic dysfunction in depression: potential therapeutic targets." Science, 338(6103), 68-72.
  3. Zarate, C. A., et al. (2006). "A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression." Archives of General Psychiatry, 63(8), 856-864.
  4. Canuso, C. M., et al. (2018). "Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality." American Journal of Psychiatry, 175(7), 620-630.
Your Options

Types of Ketamine Treatment

There are three primary ways ketamine is administered for depression treatment, each with distinct advantages, limitations, and cost structures. Understanding these differences is essential to choosing the right approach for your situation.

IV Ketamine Infusion

In-Clinic

Intravenous ketamine infusions are administered in a clinical setting — typically a specialized ketamine clinic or hospital outpatient center. A standard protocol involves six infusions over 2-3 weeks, each lasting approximately 40 minutes to one hour. The dosage (usually 0.5 mg/kg) is delivered slowly via IV drip while vital signs are monitored.

Advantages

  • Precise dosing with real-time adjustment capability
  • Highest bioavailability of any administration route (~100%)
  • Continuous medical monitoring throughout the session
  • Most extensively studied in clinical research
  • Strongest evidence base for rapid-acting antidepressant effects

Limitations

  • Requires travel to a clinic for each session
  • Most expensive option: $400-$800 per infusion ($2,400-$4,800 for initial series)
  • Generally not covered by insurance
  • Time commitment of 2-3 hours per session (including recovery)
  • Maintenance infusions typically needed every 2-6 weeks
Typical Cost $400-$800 per infusion

Nasal Spray (Spravato / Esketamine)

FDA-Approved

Spravato (esketamine) is an FDA-approved nasal spray specifically indicated for treatment-resistant depression. It uses esketamine, the S-enantiomer of ketamine. Treatment is self-administered under supervision in a certified healthcare facility through the REMS (Risk Evaluation and Mitigation Strategy) program. Patients must remain at the facility for at least 2 hours after each dose for monitoring.

Advantages

  • FDA-approved specifically for TRD (and depression with suicidal ideation)
  • May be partially or fully covered by insurance with prior authorization
  • Non-invasive nasal spray administration
  • Standardized treatment protocol
  • Extensive safety data from clinical trials and post-market surveillance

Limitations

  • Must be administered at a certified REMS facility — cannot take home
  • Required 2-hour observation period after each administration
  • Copays can still be substantial even with insurance coverage
  • Limited dosing flexibility (56 mg or 84 mg fixed doses)
  • Twice-weekly sessions for first month, then weekly or biweekly
Typical Cost $590-$885 per session (before insurance)

Sublingual / Oral Ketamine (At-Home)

Most Accessible

At-home ketamine therapy involves sublingual (under-the-tongue) tablets or troches prescribed by a licensed provider through telehealth and delivered to your door by a compounding pharmacy. Treatment sessions are conducted at home with remote medical monitoring, regular check-ins, and provider-guided dosage adjustments. This approach has become increasingly popular due to its convenience and affordability.

Advantages

  • Most affordable option for ongoing treatment ($124-$149/month for subscriptions)
  • No travel required — treat from the comfort and privacy of home
  • Flexible scheduling that fits your life
  • Ongoing provider monitoring and dosage adjustment
  • Lower barrier to maintaining consistent treatment schedule
  • Particularly valuable for patients in areas without nearby ketamine clinics

Limitations

  • Lower bioavailability than IV (~30% sublingual vs ~100% IV)
  • Requires self-discipline to follow treatment protocols
  • No in-person medical supervision during sessions
  • Should have a trusted person present during initial sessions
  • Not appropriate for all patients (requires thorough screening)
Typical Cost $124-$1,495+/month depending on provider

Considering At-Home Ketamine for TRD?

Kalm Health offers affordable, no-cap ketamine therapy starting at $124/month with a free consultation.

Learn More About Kalm Health →
Self-Assessment

Is At-Home Ketamine Right for You?

At-home ketamine has made this breakthrough treatment accessible to millions of patients who previously couldn't access it due to cost, location, or scheduling constraints. However, it's not appropriate for everyone. Here's what you should consider when evaluating whether at-home treatment is a good fit for your situation.

Who Typically Qualifies

Most at-home ketamine providers require patients to meet the following general criteria:

  • Diagnosed with treatment-resistant depression or major depressive disorder that has not responded adequately to at least one previous treatment
  • Age 18 or older (some providers require 21+)
  • No active substance use disorder, particularly with dissociative drugs
  • No uncontrolled hypertension — blood pressure should be managed before starting treatment
  • No history of psychotic disorders such as schizophrenia or schizoaffective disorder
  • Not currently pregnant or planning pregnancy
  • Stable living situation with a safe, quiet space for treatment sessions
  • Willingness to have a trusted person present during at least the initial sessions

The Screening Process

Reputable at-home ketamine providers conduct thorough medical evaluations before prescribing. This typically includes a comprehensive health questionnaire, review of your complete medication list, psychiatric history evaluation, and a video consultation with a licensed prescriber. Some providers also require baseline lab work or vital sign measurements. Be cautious of any service that prescribes ketamine without a meaningful medical evaluation.

What to Expect During Treatment

A typical at-home ketamine session involves placing a sublingual tablet under your tongue and allowing it to dissolve over 10-15 minutes. Effects begin within 15-30 minutes and typically last 1-2 hours. During this time, you may experience altered perception, a sense of floating or detachment, and changes in how you process emotions and thoughts. Most patients describe the experience as deeply reflective. You should not drive, operate machinery, or make important decisions for at least 6 hours after a session.

Important Safety Considerations

Safety First

  • Always follow your provider's dosing instructions exactly
  • Have a sober, trusted person (a "session sitter") present, especially for your first few sessions
  • Treat in a safe, comfortable environment — remove trip hazards, have water nearby
  • Do not combine with alcohol, benzodiazepines, or recreational drugs
  • Report any concerning side effects to your provider immediately
  • Keep all follow-up appointments and be honest about your experience
  • Store medication securely and never share it with others
Provider Comparison

At-Home Ketamine Providers for TRD

Choosing the right provider is one of the most important decisions in your treatment journey. For patients with treatment-resistant depression specifically, factors like dosing flexibility, cost sustainability, and ongoing medical support are critical. Here's how the leading providers compare for TRD patients.

Best Value for TRD

Kalm Health

$124 /month

Kalm Health stands out for TRD patients specifically because of its combination of low cost, no dose cap, and $0 initial consultation. Treatment-resistant depression often requires higher doses and longer treatment timelines than standard depression, making these factors especially important.

  • No dose cap — critical for TRD patients who often need higher doses
  • $0 consultation fee to start
  • Licensed provider monitoring and dosage adjustments
  • Monthly subscription with no long-term commitment
  • Medication + provider visits included in price
  • Compounding pharmacy ships directly to you
Why this matters for TRD: Many TRD patients find their optimal dose is higher than the starting dose. Providers with dose caps can leave TRD patients undertreated. Kalm's no-cap policy allows providers to titrate to the dose that actually works for each individual patient.
Visit Kalm Health

Joyous

$129 /month

Joyous offers a low-dose ketamine protocol at a competitive price point. Their approach focuses on sub-perceptual microdosing, which some patients prefer for the gentler experience. However, TRD patients should be aware of the dose limitations.

  • Daily low-dose (microdose) protocol
  • Simple subscription model
  • Provider check-ins via app
  • Dose cap may limit effectiveness for TRD patients
  • Low-dose approach may not reach therapeutic threshold for severe TRD
TRD consideration: Joyous's dose cap and microdosing focus can be a meaningful limitation for treatment-resistant patients. Research on ketamine for TRD has primarily used moderate to higher doses, and some TRD patients need doses above what Joyous provides.

Mindbloom

$1,176+ program

Mindbloom offers a more structured, guided program that includes clinician consultations, a "guide" (peer support), and integration exercises. The higher price reflects this more comprehensive approach, which some patients find valuable for the additional support structure.

  • Structured 6-session program with guided support
  • Peer "guide" assigned to each patient
  • Integration and journaling tools
  • Clinician-led treatment planning
  • Significantly higher cost limits long-term sustainability
  • Program structure may not align with ongoing TRD management needs
TRD consideration: While the structured program provides good support, TRD often requires long-term ongoing treatment. At $1,176+ per program cycle, the annual cost can be prohibitive for sustained therapy.

Nue Life

$1,495+ program

Nue Life positions itself as a premium, comprehensive program that includes health coaching, group integration sessions, neuroplasticity-based aftercare, and extensive clinical support. Their approach emphasizes the full therapeutic journey, not just the medication.

  • Comprehensive program with health coaching
  • Group integration sessions
  • Neuroplasticity-focused aftercare program
  • Music-guided treatment experiences
  • Highest cost among at-home providers
  • Premium pricing challenging for long-term TRD treatment
TRD consideration: The comprehensive approach includes many valuable elements, but the premium price point makes it the most expensive option for the long-term treatment that TRD typically requires.

Other Providers Worth Noting

Several other at-home ketamine providers serve the market, including Peak, Better U, and Wondermed. These services vary in pricing, dosing protocols, and support levels. When evaluating any provider for TRD specifically, prioritize: (1) dosing flexibility to reach therapeutic levels, (2) cost sustainability for ongoing treatment, (3) quality of medical oversight, and (4) responsiveness to dose adjustment requests.

Clinical Evidence

What the Research Says

The evidence supporting ketamine for treatment-resistant depression has grown substantially over the past two decades. What began as a surprising finding in a small pilot study has been replicated across dozens of randomized controlled trials, meta-analyses, and real-world effectiveness studies. Here's a summary of the most important findings.

Response and Remission Rates

Across multiple clinical trials, IV ketamine has demonstrated response rates of 60-70% in patients with treatment-resistant depression. "Response" is clinically defined as a 50% or greater reduction in depression severity as measured by standardized scales like the Montgomery-Asberg Depression Rating Scale (MADRS) or the Hamilton Depression Rating Scale (HAM-D). Remission rates — meaning depression scores falling below the clinical threshold entirely — have been reported at 30-40% in TRD populations.

These numbers are particularly impressive when you consider the context: these are patients who have already failed multiple other treatments. For comparison, each successive antidepressant trial in treatment-resistant patients typically yields response rates of only 10-15%. Ketamine's response rate of 60-70% in this same population represents a dramatic improvement over the standard of care.

Key Studies and Findings

Zarate et al., 2006 (NIMH)

The landmark randomized, placebo-controlled trial that established IV ketamine as a rapid-acting antidepressant. Patients with TRD showed significant improvement within 2 hours of a single infusion, with effects lasting up to one week. This study was published in the Archives of General Psychiatry and is considered the foundational study for the field.

Murrough et al., 2013 (Mount Sinai)

A larger randomized controlled trial comparing IV ketamine to an active placebo (midazolam). Ketamine showed a response rate of 64% compared to 28% for the active placebo at 24 hours, providing robust evidence that ketamine's effects are not simply due to its psychoactive properties.

Daly et al., 2018 (Janssen / Phase III Spravato trials)

The pivotal Phase III trials that led to FDA approval of intranasal esketamine (Spravato) for TRD. These multi-site studies demonstrated that esketamine combined with a new oral antidepressant was significantly superior to a new oral antidepressant alone in reducing depression symptoms.

Wilkinson et al., 2017 (Yale Meta-Analysis)

A comprehensive meta-analysis of all available randomized controlled trials of ketamine for depression, confirming large antidepressant effects with rapid onset. The analysis found that ketamine was significantly more effective than both saline placebo and active placebo controls.

Duration of Effects and Maintenance Treatment

One of the key clinical questions has been how long ketamine's antidepressant effects last. Research shows that the effects of a single IV infusion typically persist for 1 to 3 weeks, with most patients experiencing some return of symptoms after 7-14 days. This has led to the development of maintenance treatment protocols, where patients receive regular boosters (IV infusions every 2-6 weeks, or ongoing at-home sublingual treatment) to sustain improvement.

A 2019 study published in the American Journal of Psychiatry found that patients who responded to an initial series of esketamine treatments and continued maintenance dosing had significantly lower relapse rates than those who discontinued treatment, supporting the importance of ongoing therapy for sustained benefit in TRD patients.

Safety Profile

The most common side effects of ketamine treatment include temporary dissociation, dizziness, nausea, increased blood pressure, and sedation. These effects are typically mild to moderate and resolve within 1-2 hours after treatment. Serious adverse events are rare when ketamine is administered under appropriate medical supervision. Long-term safety data, including studies examining bladder health and cognitive function, have been reassuring at the doses used for depression treatment, though ongoing monitoring remains standard practice.

Comprehensive Approach

Combining Ketamine with Other Treatments

While ketamine can produce powerful antidepressant effects on its own, research and clinical experience suggest that the best outcomes occur when ketamine is part of a comprehensive treatment approach. Here are the most evidence-supported complementary strategies.

Psychotherapy

Combining ketamine with psychotherapy — particularly during the window of enhanced neuroplasticity that follows a ketamine session — may amplify and extend its benefits. This approach, sometimes called ketamine-assisted psychotherapy (KAP), leverages ketamine's ability to increase cognitive flexibility and emotional openness. Cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and psychodynamic approaches have all been used effectively alongside ketamine treatment. Many patients report that insights gained during or shortly after ketamine sessions can be more readily integrated into lasting change when processed with a skilled therapist.

Lifestyle Modifications

Several lifestyle factors have strong evidence for supporting depression treatment and may enhance ketamine's effects:

  • Regular exercise: Aerobic exercise increases BDNF levels through many of the same pathways activated by ketamine, potentially reinforcing neuroplastic changes
  • Sleep optimization: Depression and sleep disorders are closely linked; improving sleep hygiene can support treatment response
  • Nutrition: An anti-inflammatory diet rich in omega-3 fatty acids, fruits, vegetables, and whole grains supports brain health
  • Stress management: Mindfulness meditation, yoga, and other stress-reduction practices can help maintain treatment gains
  • Social connection: Rebuilding social bonds, even gradually, counteracts the isolation that worsens depression

Other Medications

Ketamine is often used alongside existing psychiatric medications. Many patients continue their current antidepressants while adding ketamine therapy, and some research suggests that the combination may be more effective than either alone. However, it's essential to work with your prescribing provider to manage potential interactions, particularly with MAOIs, lithium, and certain other medications. Some patients are eventually able to reduce or discontinue other antidepressants under medical guidance as their depression improves with ketamine, but this should never be done without professional supervision.

Building Your Treatment Team

For the best outcomes with TRD, consider building a treatment team that includes: a ketamine prescriber for medication management, a therapist experienced with depression and ideally familiar with ketamine-assisted therapy, and your primary care provider to coordinate overall health. Open communication between these providers leads to more coordinated, effective care.

Common Questions

Frequently Asked Questions

What is treatment-resistant depression (TRD)?

Treatment-resistant depression is defined as major depressive disorder (MDD) that has not responded adequately to at least two different antidepressant medications taken at therapeutic doses for sufficient duration (typically 6-8 weeks each). Approximately 30% of people with MDD meet this criteria. The diagnosis is not a commentary on the patient's effort or character — it reflects the biological complexity of depression and the limitations of medications that all target the same neurotransmitter systems.

How does ketamine treat depression differently than traditional antidepressants?

Traditional antidepressants target serotonin, norepinephrine, or dopamine systems and take 4-8 weeks to show effects. Ketamine works on the glutamate system via NMDA receptor antagonism, promoting rapid neuroplasticity and synaptogenesis. Rather than simply adjusting neurotransmitter levels, ketamine helps the brain rebuild damaged synaptic connections. Many patients experience meaningful relief within hours to days rather than weeks.

What are the different types of ketamine treatment available?

There are three main types: IV ketamine infusions administered in clinical settings (most studied, highest bioavailability, most expensive), intranasal esketamine (Spravato) which is FDA-approved for TRD and administered in certified facilities, and sublingual/oral ketamine tablets that can be taken at home under medical supervision through telehealth providers (most accessible and affordable for ongoing treatment).

How quickly does ketamine work for depression?

Many patients report noticeable improvement within hours to days of their first treatment. Clinical studies have shown significant reduction in depression scores within 24 hours of a single ketamine dose. This rapid onset is one of ketamine's most significant advantages over traditional antidepressants and can be particularly important for patients experiencing suicidal ideation.

Is at-home ketamine safe for treatment-resistant depression?

At-home ketamine can be safe when prescribed and monitored by licensed medical providers through reputable telehealth services. These providers require thorough medical screening, regular check-ins, and have safety protocols in place. Patients should always have a trusted person present during sessions (especially early sessions), follow all provider guidelines carefully, and never combine ketamine with alcohol or other substances.

How much does ketamine treatment cost?

Costs vary significantly by treatment type. IV infusions typically run $400-800 per session, with 4-6 initial sessions recommended ($1,600-$4,800). Spravato may be partially covered by insurance but can cost $590-885 per session before coverage. At-home oral ketamine services range from $124-149/month for subscription models (like Kalm Health at $124/mo) to $1,176-1,495+ for structured programs. For TRD patients requiring long-term treatment, subscription models tend to be most cost-effective.

What is the success rate of ketamine for treatment-resistant depression?

Clinical studies report response rates of 60-70% for ketamine in TRD patients, meaning a 50% or greater reduction in depression severity. Remission rates (full resolution of depressive symptoms) are approximately 30-40%. These figures are remarkable considering that each successive antidepressant trial in TRD patients typically yields only 10-15% response rates. Individual results vary based on dosing, treatment duration, concurrent therapies, and other individual factors.

Can I take ketamine with my current antidepressants?

In many cases, ketamine can be used alongside existing antidepressant medications, and some research suggests the combination may be beneficial. However, there are important interactions to consider. MAOIs require special caution, and certain other medications may need adjustment. Your prescribing provider will review your full medication list and medical history before prescribing ketamine and will advise you on any necessary changes.

How long do the effects of ketamine treatment last?

The antidepressant effects of a single ketamine treatment typically last 1-3 weeks. With ongoing maintenance treatment — whether regular IV boosters or consistent at-home sublingual therapy — many patients maintain significant improvement over the long term. Some patients eventually reduce treatment frequency as they develop complementary coping strategies and lifestyle changes, while others benefit from continued regular sessions.

Who should not use ketamine for depression?

Ketamine may not be appropriate for people with uncontrolled hypertension, active substance use disorders (particularly with ketamine, PCP, or other dissociative drugs), certain psychotic disorders (schizophrenia, schizoaffective disorder), pregnancy or planned pregnancy, severe liver disease, or unstable cardiovascular conditions. A thorough medical evaluation by a qualified provider is required before starting any form of ketamine treatment.

Does insurance cover ketamine treatment for depression?

Insurance coverage varies by treatment type. Spravato (intranasal esketamine) is FDA-approved for TRD and may be covered by insurance plans, though prior authorization is usually required and copays can still be substantial. IV ketamine infusions and at-home oral/sublingual ketamine are generally considered off-label uses and are typically not covered by insurance. However, the affordability of subscription-based at-home providers (as low as $124/month) makes treatment accessible even without insurance coverage.

What does a ketamine therapy session feel like?

During a ketamine session, patients typically experience a dissociative state that may include altered perception of time and space, floating or weightlessness sensations, visual or auditory changes, and shifts in how they process thoughts and emotions. Many patients describe a sense of emotional distance from their problems that allows new perspectives. Sessions usually last 1-2 hours for the active experience. Side effects like mild nausea, dizziness, or elevated blood pressure typically resolve quickly after the session ends. Most patients describe the experience as tolerable to deeply meaningful.

Ready to Try Ketamine for Your TRD?

Kalm Health offers at-home ketamine therapy with no dose cap, $124/month, and a free consultation. Licensed in all 50 states with board-certified providers.

Start Your Free Consultation →

No commitment. No dose cap. Cancel anytime.